Published 1 year ago

Baudax Bio Announces Pricing of $5 Million Public Offering - Baudax Bio (NASDAQ:BXRX)

Summary by Ground News

Baudax Bio, Inc. is a pharmaceutical company focused on therapeutics for acute care settings. BXRX announced the pricing of a public offering of an aggregate of 1,042,787 shares of its common stock. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5 million.

0 Articles

All

Left

Center

Right

Benzinga

Baudax Bio Announces Pricing of $5 Million Public Offering - Baudax Bio (NASDAQ:BXRX)

MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the "Company" or "Baudax Bio") (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of a public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042…

1 year ago·New York, United States

Read Full Article

Globe Newswire

Baudax Bio Announces Pricing of $5 Million Public Offering

MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on...

1 year ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.